Login
$FULC
$3.72 +$0.01 (0.27%) After hours

$FULC 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Other Events

On November 7, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, and Slate Medicines, Inc., or Slate, entered into an asset purchase agreement providing for the sale of Fulcrum’s early-stage fetal hemoglobin, or HbF, assets to an unaffiliate...

17 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 16, 2026, by and among Slate Medicines, Inc., a Delaware corporation (the “Company”), and each of the Persons listed on Exhibit A attached to this Agreement (eac...

10 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed with Fulcrum that Mr. To...

25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Fulcrum Therapeutics, Inc., or Fulcrum, held on June 24, 2026, or the Annual Meeting.

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed, on May 31, 2026, the board of directors, or Board, of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the ...

04 Jun 2026 8-K: Costs Associated with Exit or Disposal Activities; Other Events

On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of po...

01 Jun 2026 8-K: Other Events

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

27 Apr 2026 8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ―

24 Feb 2026 8-K: Results of Operations and Financial Condition

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substan...

11 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

29 Oct 2025 8-K: Results of Operations and Financial Condition

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―

28 Aug 2025 8-K: Regulation FD Disclosure

Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substan...

29 Jul 2025 8-K: Results of Operations and Financial Condition; Other Events

― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ―

27 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The following is a summary of the matters voted on at the 2025 annual meeting of stockholders of Fulcrum Therapeutics, Inc., or Fulcrum, held on June 26, 2025, or the Annual Meeting.

01 May 2025 8-K: Results of Operations and Financial Condition

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―

04 Mar 2025 8-K: Termination of a Material Definitive Agreement

On February 26, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, received written notice from MyoKardia, Inc., or MyoKardia, of its election to terminate for convenience the collaboration and license agreement dated July 20, 2020, as amende...

25 Feb 2025 8-K: Results of Operations and Financial Condition

― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025, and the 20 mg dose cohort by the end of 2025 ―

13 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

FULCRUM THERAPEUTICS Disclaimer and Notice This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including exp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support